mothertobaby semaglutide pregnancy fact sheet 2025 Metabolic dysfunction–associated steatotic liver disease and Ep. 84 - GLP-1 Medications

Consider what this means in the context of the butyrate-GLP-1 pathway: JUVIA supports microbiome diversity and balance, laying the foundation for robust bacterial fermentation

Research shows that people using GLP-1 therapy can unintentionally eat too little protein, fiber, or micronutrients (like calcium, magnesium, and vitamins A, D, E, and K) as appetite and total food intake decrease

Hypertonic saline and desmopressin: A simple strategy for safe correction of severe hyponatremia

Matt Levy, recently presented groundbreaking analysis using Helix data to identify key metabolic and genetic factors associated with weight loss in semaglutide, evaluated the impact of established BMI polygenic risk scores (PGS), and more

As a fixed-dose combination, CagriSema was assessed in two phase 3 studies (REDEFINE 1 and 2), resulting in significant and clinically relevant reductions in body weight compared with placebo in adults with overweight or obesity, with [8] or without type 2 diabetes [9]